Estimating scaled treatment effects with multiple outcomes by Kennedy, Edward H. et al.
Estimating scaled treatment effects
with multiple outcomes
Edward H. Kennedy ∗
Department of Statistics, Carnegie Mellon University
Shreya Kangovi
Division of General Internal Medicine, University of Pennsylvania
Nandita Mitra
Department of Biostatistics & Epidemiology, University of Pennsylvania
Abstract
In classical study designs, the aim is often to learn about the effects of a treat-
ment or intervention on a single outcome; in many modern studies, however, data
on multiple outcomes are collected and it is of interest to explore effects on multiple
outcomes simultaneously. Such designs can be particularly useful in patient-centered
research, where different outcomes might be more or less important to different pa-
tients. In this paper we propose scaled effect measures (via potential outcomes)
that translate effects on multiple outcomes to a common scale, using mean-variance
and median-interquartile-range -based standardizations. We present efficient, non-
parametric, doubly robust methods for estimating these scaled effects (and weighted
average summary measures), and for testing the null hypothesis that treatment affects
all outcomes equally. We also discuss methods for exploring how treatment effects
depend on covariates (i.e., effect modification). In addition to describing efficiency
theory for our estimands and the asymptotic behavior of our estimators, we illustrate
the methods in a simulation study and a data analysis. Importantly, and in contrast
to much of the literature concerning effects on multiple outcomes, our methods are
nonparametric and can be used not only in randomized trials to yield increased ef-
ficiency, but also in observational studies with high-dimensional covariates to reduce
confounding bias.
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policy evaluation.
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1 Introduction
In classical study designs, the aim is often to learn about the effects of a treatment or inter-
vention on a single outcome; in many modern studies, however, data on multiple outcomes
are collected and it is of interest to explore effects on multiple outcomes simultaneously.
Such designs are particularly important in patient-centered research, for example, where
different outcomes might be more or less important to different patients (Kangovi et al.
2014; Kangovi et al. 2017), and more generally in prioritizing public health recommenda-
tions (VanderWeele 2017).
There has been varied and relatively extensive discussion in the literature over the past
few decades about estimating treatment effects on multiple outcomes (O’Brien 1984; Pocock
et al. 1987; Sammel et al. 1999; Freemantle et al. 2003; Thurston et al. 2009; Teixeira-Pinto
& Mauri 2011; Yoon et al. 2011), including estimating scaled effects (Lin et al. 2000; Roy et
al. 2003), which is a major focus of this paper. However, most of the aforementioned work
requires strong parametric assumptions and is geared towards randomized trials rather than
observational studies, which can require adjustment for high-dimensional confounders. In
contrast, we consider nonparametric doubly robust methods for estimation and hypothesis
testing of scaled treatment effects on multiple outcomes. In particular we translate effects
to a common scale with mean-variance and median-interquartile-range -based standard-
izations, which are constructed within an explicitly causal potential outcomes framework.
Our work is a response to recent proposals by VanderWeele (2017) and others to spend
more effort exploring effects of interventions on multiple outcomes simultaneously, rather
than using the classical one-outcome-at-a-time approach. Importantly our work is designed
to accommodate modern studies that include complex covariate information, which can be
leveraged for efficiency gains or to reduce confounding bias (or both).
The setup of the paper is as follows. In Sections 3.1 and 3.2 we present efficient doubly
robust methods for estimating our proposed scaled effects (along with weighted average
summary measures in Section 3.5), as well as methods for testing the null hypothesis
that treatment affects all outcomes equally in Section 3.3. We also discuss approaches for
exploring how treatment effects vary with covariates (i.e., effect modification) in Section 3.4.
In addition to describing efficiency theory for our estimands and the asymptotic behavior of
our estimators, in Section 4 we illustrate the methods in a simulation study and in Section
5 we apply them to a recently conducted trial evaluating the effect of community health
workers on various health outcomes in a low income population.
2 Setup
2.1 Data & Notation
We suppose we observe an independent and identically distributed sample (Z1, ...,Zn),
where each observation Z = (X, A,Y) consists of a vector of p covariates X = (X1, ..., Xp),
a binary treatment A, and a vector of K outcomes Y = (Y1, .., YK). We characterize
treatment effects using potential outcome notation (Rubin 1974), letting Ya = (Y a1 , ..., Y
a
K)
denote the outcome vector that would have been observed under treatment level a.
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We use P to denote the distribution of Z = (X, A,Y), and write expectations under
P with usual E operator notation. For a generic random variable U we define standard
deviations as usual with sd(U) =
√
E(U2)− E(U)2. We use Pn to denote the empirical
measure so that sample averages can be written as 1
n
∑
i f(Zi) = Pn{f(Z)}. Finally we use
the following notation to simplify the presentation:
pi(a | x) = P(A = a | X = x)
µk(x, a) = E(Yk | X = x, A = a)
ηk(x, a) = E(Y 2k | X = x, A = a).
2.2 Identification
Throughout this paper we consider estimating quantities defined in terms of the distribu-
tions of potential outcomes Ya for a = 0, 1. Since potential outcomes are not observed
directly, we need identifying assumptions to express estimands of interest in terms of the
estimable observed data distribution. We consider the usual ignorability or “no unmeasured
confounding” setting, in which the following assumptions hold for a = 0, 1:
Assumption 1. Consistency: A = a implies Y = Ya.
Assumption 2. Positivity: P{0 < pi(a | X) < 1} = 1 for all a.
Assumption 3. Exchangeability: A ⊥⊥ Ya | X.
Assumptions 1–3 can hold by design in a randomized trial, since treatment A is under
the control of investigators. However in observational studies these assumptions can be
violated, and are generally untestable (apart from positivity). Consistency means poten-
tial outcomes are defined uniquely by subjects’ own treatment levels (this can be violated
in, for example, vaccine studies). Positivity means treatment is not assigned determinis-
tically for any subjects, regardless of covariates. Exchangeability means treatment is as
good as randomized (within covariate strata) since it is unrelated to potential outcomes
once we condition on covariates. Exchangeability requires either external randomization of
treatment, or else the collection of sufficiently many relevant covariates.
Assumptions 1–3 have been discussed at length elsewhere, and it is well-known that
they imply
P(Ya ≤ y | X) = P(Y ≤ y | X, A = a),
i.e., the conditional distribution of potential outcomes under A = a (given covariates)
equals the conditional distribution of observed outcomes (given covariates) among those
for whom A = a observationally. For example this fact also implies that E(Ya) = E{E(Y |
X, A = a)} and similarly for other marginal quantities.
3 Methodology
In this section we present scaled treatment effect parameters and estimators, discuss how
to test for differential effects across multiple outcomes, give extensions for exploring how
treatment effects vary with covariates, and finally present weighted average measures that
can provide a scalar summary of multivariate effects.
2
3.1 Scaled Average Effects
We start by presenting a scaled treatment effect parameter (using mean-variance standard-
ization), discuss corresponding semiparametric efficiency theory, give doubly robust and
locally efficient estimators, and describe asymptotic properties.
As noted for example by Lin et al. (2000) and Roy et al. (2003), usual outcome-specific
effects cannot be compared directly in studies with multiple outcomes measured on different
scales. For example, average differences of the form E(Y 1k −Y 0k ) will generally have different
and non-comparable units (e.g., kilograms for k = 1 and millimeters of mercury for k = 2).
Thus, to generate a unitless measure of effect, we propose a simple standardization by the
standard deviation of outcomes Y 0k under control. Note that this is most useful in settings
where A = 0 represents a meaningful control group (e.g., standard of care), rather than an
alternative and potentially comparable treatment option.
Specifically we characterize effects on outcome k with the scaled effect measure
ψk =
E(Y 1k − Y 0k )
sd(Y 0k )
. (1)
This effect measure captures the mean difference in outcomes under treatment versus con-
trol, expressed in terms of the standard deviation under control. Thus ψk = 1 indicates
that treatment increases outcomes by one standard deviation, on average, of what they
would have been under control; similarly ψk = 2 means treatment increases outcomes by
two standard deviations on average, and ψk = −1 means treatment decreases outcomes by
one standard deviation. Scaled effect measures have played an important role in studies
with multiple outcomes (Lin et al. 2000; Roy et al. 2003), however so far they have only
been proposed within the context of parametric models. Our work can thus be viewed as
a nonparametric extension, which also admits doubly robust estimators.
We can use results from semiparametric theory (Bickel et al. 1993; van der Laan &
Robins 2003; Tsiatis 2006) to construct optimal estimators for ψk under minimal assump-
tions about the distribution of the data P. We refer to Kennedy (2016) for a review. First
define, for a = 0, 1,
φak(Z; pi, µ) =
1(A = a)
pi(a | X)
{
Yk − µk(X, a)
}
+ µk(X, a) (2)
φ2k(Z; pi, η) =
1(A = 0)
pi(0 | X)
{
Y 2k − ηk(X, 0)
}
+ ηk(X, 0). (3)
as components of the efficient influence functions for E(Y ak ) and E{(Y 0k )2}, respectively.
Then, given estimators (pˆi, µˆ, ηˆ) of the nuisance functions, the estimator
ψˆk =
Pn
{
φ1k(Z; pˆi, µˆ)− φ0k(Z; pˆi, µˆ)
}
√
Pn
{
φ2k(Z; pˆi, ηˆ)
}
−
[
Pn
{
φ0k(Z; pˆi, µˆ)
}]2 (4)
is doubly robust and locally efficient, under nonparametric models as well as models that
put some (e.g., parametric) restrictions on the treatment mechanism pi. We will now discuss
these properties in more detail, proofs of which are given in the Supplementary Materials.
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Double robustness is a very important property that has been discussed in detail before
(Robins & Rotnitzky 2001; Bang & Robins 2005). One important consequence of double
robustness is that analysts have two chances at obtaining a consistent estimator. For
example, in our case, the estimator ψˆk is consistent for its target ψk as long as either of
the nuisance estimators pˆi or (µˆ, ηˆ) are consistent, even if one of pˆi or (µˆ, ηˆ) is misspecified.
In particular, this means consistency of ψˆk is guaranteed in a randomized trial, since there
pi is known and thus can be estimated consistently under no assumptions. We prove that
our estimator is doubly robust in Section 1 of the Supplementary Materials.
Another crucially important property of doubly robust estimators is that they can at-
tain fast parametric
√
n rates of convergence even after machine learning-based covariate
adjustment (van der Laan & Rose 2011). This is not the case for most standard plug-in
estimators, which typically inherit slower-than-
√
n convergence rates from their nuisance
estimators (van der Vaart 2014). In contrast, our proposed estimator ψˆk will be
√
n-
consistent and asymptotically normal even if the nuisance functions (pˆi, µˆ, ηˆ) are estimated
flexibly with nonparametric or machine learning methods, as long as these nuisance esti-
mators converge at faster than n1/4 rates (and under some empirical process conditions,
which can be avoided with sample splitting).
In particular, under the above conditions and other standard regularity conditions given
in the Supplementary Materials, ψˆk is asymptotically normal,√
n(ψˆk − ψk) N(0, σ2k), (5)
with asymptotic variance σ2k equal to the variance of the efficient influence function, which
is given by ϕk(Z; pi, µ, η) defined as
φ1k(Z; pi, µ)− φ0k(Z; pi, µ)
sd(Y 0k )
− ψk
[
φ2k(Z; pi, η) + E{(Y 0k )2} − 2E(Y 0k )φ0k(Z; pi, µ)
2 sd(Y 0k )
2
]
. (6)
Thus Wald-type confidence intervals for ψk can be constructed by estimating the asymp-
totic variance σ2k with the empirical variance of the estimated efficient influence function
values (obtained by replacing unknown quantities in (6) with estimates). The asymptotic
normality result (5) is proved in Section 2 of the Supplementary Materials, using empirical
process theory (van der Vaart & Wellner 1996; van der Vaart 2000) to allow for flexible
nonparametric estimation of (pˆi, µˆ, ηˆ). We prove that (6) is in fact the efficient influence
function in Section 3 of the Supplementary Materials, which (given the asymptotic nor-
mality result) implies that ψˆk is locally efficient. In particular ψˆk is locally semiparametric
efficient under models that put at most some restrictions on the treatment mechanism
(including for example nonparametric models, as well as models in which the treatment
mechanism is known).
Finally, in Section 6 of the Supplementary Materials we give easily implementable R
code for computing ψˆk based on estimating equations and targeted maximum likelihood
(TMLE) (van der Laan & Rubin 2006; van der Laan & Rose 2011). TMLE uses specially
constructed nuisance estimates (µˆ∗, ηˆ∗) that insure that resulting estimators of the numera-
tor and denominator of (4) respect the bounds of the parameter space (e.g., the numerator
must lie between [−1, 1] when Yk ∈ [0, 1]), which can improve finite-sample properties
and lessen the impact of extreme propensity scores. The provided code also calculates
confidence intervals based on the approach described in the previous paragraph.
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3.2 Scaled Quantile Effects
In some cases, the mean and variance are not useful measures of centrality and spread
(e.g., for distributions that are highly skewed), in which case the standardization given in
(1) may not be most appropriate. An alternative quantile-based standardization that is
immune to such concerns is given by
ψqk =
M(Y 1k )−M(Y 0k )
iqr(Y 0k )
, (7)
where for arbitrary random variable U with distribution function F (u) = P (U ≤ u), we
define ξ(q) = inf{u : q ≤ F (u)} as the q-th quantile, and let M(U) = ξ(0.50) denote
the median and iqr(U) = ξ(0.75) − ξ(0.25) denote the interquartile range. Therefore ψqk
captures the difference in median outcomes under treatment versus control, expressed in
terms of the interquartile range under control. For example, ψqk = 0.5 means treatment
increases the median outcome, by half the interquartile range under control.
As for the scaled average effect in (1), a doubly robust and locally efficient estimator
for the quantile effect ψqk is given by
ψˆqk =
Fˆ−11k (0.50)− Fˆ−10k (0.50)
Fˆ−10k (0.75)− Fˆ−10k (0.25)
(8)
where Fˆ−1ak (·) is the inverse of Fˆak(y) = Pn{φ(y)ak (Z; pˆi, νˆ)} (up to order oP(1/
√
n) if exact
solutions cannot be found), for
φ
(y)
ak (Z; pi, ν) =
1(A = a)
pi(a | X)
{
1(Yk ≤ y)− νk(y | X, a)
}
+ νk(y | X, a) (9)
where νk(y | X, a) = P(Yk ≤ y | X = x, A = a). We give the efficient influence function for
ψqk (as well as conditions under which this is the influence function for ψˆ
q
k) in Section 4 of
the Supplementary Materials; results for unscaled effects were developed by Dı´az (2015).
3.3 Hypothesis Testing
In what follows, we suppose for concreteness that the mean-variance standardization in
(1) is appropriate for all K outcomes. However, all results can be equally extended to
the quantile-based standardization given in (7) (if mean-variance standardization is only
appropriate for some covariates, we suggest using quantile-based standardization for all).
As mentioned in the Introduction, in studies with multiple outcomes it is often of
interest to assess whether any outcomes are differentially affected by treatment, and if so,
which outcomes. Additional motivation is given in Section 5, as well as by Lin et al. (2000)
and Roy et al. (2003). This goal can be accomplished by testing a hypothesis of the form
H0 : ψ1 = ψ2 = ... = ψK (10)
which says that all scaled treatment effects are equal. Recall that this is a meaningful
hypothesis even if outcomes are measured on different scales, due to the fact that the
scaled effects are unitless after dividing by standard deviations under control.
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A doubly robust test of the hypothesis in (10) can be constructed based on the asymp-
totic distribution of
Tn = n(Cψˆ)
T(CΣˆCT)−1(Cψˆ), (11)
where C is a (K − 1) × K banded matrix with elements Cij = 1(i = j) − 1(i = j − 1),
ψˆ = (ψˆ1, ..., ψˆK)
T, and Σˆ is an estimator of the asymptotic variance Σ of ψˆ (estimation of
which is discussed in the next paragraph). Specifically, under conditions given in Sections
2 and 5 of the Supplementary Materials, we have that
Tn  χ2K−1 (12)
under the null hypothesis H0 of homogeneous effects given in (10). Therefore an asymptotic
p-value for testing H0 is given by P (χ
2
K−1 ≥ tn), where tn is the observed value of Tn in
the sample (and χ2K−1 is a chi-squared random variable with K − 1 degrees of freedom).
If the conditions given in Sections 2 and 5 of the Supplementary Materials hold, then a
closed-form estimator for Σ can be obtained by replacing unknown quantities in (6) with
estimates and computing the empirical covariance
Σˆ = Pn
{
ϕ(Z; pˆi, µˆ, ηˆ)⊗2
}
where ϕ = (ϕ1, ..., ϕK)
T is a vector of the stacked influence functions from (6) for k =
1, ..., K, and u⊗2 = uuT for any vector u. Note that the estimated influence functions used
to construct the estimator Σˆ will also depend on estimates of Ê{(Y 0k )2} = Pn{φ2k(Z; pˆi, ηˆ)},
Ê(Y 0k ) = Pn{φ0k(Z; pˆi, µˆ)}, and ŝd(Y 0k )2 = Eˆ{(Y 0k )2} − {Eˆ(Y 0k )}2.
The conditions for the above estimator to be valid require that the product of con-
vergence rates for pˆi and (µˆ, ηˆ) is faster than
√
n, for example if pˆi is estimated with a
correct parametric model or known and (µˆ, ηˆ) is merely consistent (so that the product is
OP(1/
√
n)oP(1) = oP(1/
√
n)), or if (pˆi, µˆ, ηˆ) are all consistent and converge at faster than
n1/4 rates (so that the product is oP(n
−1/4)oP(n−1/4) = oP(1/
√
n)). There is one setting
where the above approach is valid even if this condition on the product of convergence
rates does not hold. Specifically, if pˆi is estimated with a correct parametric model, then
even if (µˆ, ηˆ) is misspecified and the estimator Σˆ is thus inconsistent, the above approach
gives conservative p-values and is still valid. This is a result of the fact that estimating the
propensity score pi when it is actually known cannot decrease (and will generally increase)
efficiency (Tsiatis 2006); thus Σˆ ≥ Σ in the sense that Σˆ−Σ is a positive definite matrix.
Alternatively the bootstrap can also be used to construct the estimator Σˆ; such an
approach would be valid as long as ψˆ is asymptotically linear, which is a weaker condition
than requiring the product of convergence rates to be oP(1/
√
n). (For example, asymptotic
linearity would hold in the scenarios discussed above, as well as if (pˆi, µˆ, ηˆ) were estimated
with parametric models and it was only assumed that either pˆi or (µˆ, ηˆ) were correctly
modeled.) In practice the bootstrap might be preferred for computing Σˆ since it depends
on weaker assumptions, although it is more computationally expensive.
To test which outcomes are differentially affected by treatment, we can test the pairwise
hypotheses Hjk : ψj = ψk. To control the family-wise error rate (which might be reasonable
if K is not too large) a simple Bonferroni correction could be used. Alternatively, to control
the false discovery rate (which might be preferable if K is large), the Benjamini-Hochberg
procedure could be used instead.
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3.4 Effect Modification
Often it is of interest to go beyond marginal effects like E(Y 1k −Y 0k ) or the scaled version in
(1), and further assess how treatment effects vary with covariates. This can be useful for
exploring the mechanism by which treatment actually works, as well as for learning how to
tailor treatment decisions to individual patient characteristics (since treatments may only
work for some patients, or may be harmful for some and beneficial for others).
A natural extension of the standard effect parameter in (1) that allows for assessing
such effect modification is given by
γk(v) =
E(Y 1k − Y 0k | V = v)
sd(Y 0k | V = v)
, (13)
where V ⊆ X is a subset of the full covariate set that only includes the variables for which
effect modification is of interest. Similar to prior subsections, this effect measures the mean
difference in outcomes under treatment versus control for those with covariates V = v, in
terms of the standard deviation under control for this same group.
When V only contains a modest number of discrete variables, the estimator in (4) can
be easily modified to estimate γk(v) with
Pn
{
φ
(v)
1k (Z; pˆi, µˆ)− φ(v)0k (Z; pˆi, µˆ)
}
√
Pn
{
φ
(v)
2k (Z; pˆi, ηˆ)
}
−
[
Pn
{
φ
(v)
0k (Z; pˆi, µˆ)
}]2 (14)
where the functions φ
(v)
ak (Z; pi, µ) = φak(Z; pi, µ)1(V = v)/Pn{1(V = v)} and φ(v)2k (Z; pi, µ) =
φ2k(Z; pi, µ)1(V = v)/Pn{1(V = v)} are v-specific versions of the influence functions from
previous sections, so that the averages in (14) are just over those units with V = v. The
influence function for the estimator in (14) is given in the next subsection.
When V contains a continuous variable or many discrete variables, the above approach
will not be feasible since the cells V = v will be very small or empty. There are a few
options for such cases. First, one could estimate E(Y ak | V) and E{(Y ak )2 | V} by regress-
ing φak(Z; pˆi, µˆ) and φ2k(Z; pˆi, ηˆ) on V using any preferred methods, such as parametric
regression modeling or flexible machine learning, and then construct
γˆk(v) =
Ê(Y 1k | V = v)− Ê(Y 0k | V = v)√
Ê{(Y 0k )2 | V = v} − {Ê(Y 0k | V = v)}2
based on these regressions. A potential disadvantage of this approach is that γˆk(v) will in
general not follow an interpretable parametric model, even if the models for the components
E(Y ak | V) and E{(Y ak )2 | V} do; e.g., the ratio of two linear models is not itself linear.
To combat this problem, one could regress the predicted values from the above approach
onto a parametric model γk(v;θ) for some θ ∈ Rq (for example, the linear model γk(v;θ) =
θTv). Alternatively, semiparametric estimators could be developed under the restriction
γk(v) = γk(v;θ); we leave this to future work. Lastly, another alternative, which is simple
and easy to implement, would be to standardize by the marginal standard deviation sd(Y 0k )
instead of the conditional form sd(Y 0k | V); this could be justified merely as an alternative
standardization or via the assumption that sd(Y 0k | V) = sd(Y 0k ).
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3.5 Weighted Average Summary Measures
So far we have discussed robust estimation of outcome-specific effects (scaled for compa-
rability) in Sections 3.1, 3.2, and 3.4, as well as testing of homogeneous effect hypotheses
in Section 3.3. In many studies it may also be useful to report a summary measure of
treatment effect across outcomes. For this purpose we propose weighted average effects of
the form
ψ∗ =
K∑
k=1
E
{
wk(V)
E(Y 1k − Y 0k | V)
sd(Y 0k | V)
}
=
K∑
k=1
E {wk(V)γk(V)} , (15)
where wk(v) is an arbitrary user-specified function that indicates how much the summary
should be weighted towards outcome k and strata V = v. For example, to weight outcomes
equally and to weight strata according to the marginal distribution of V, one could use
wk(v) = 1; if some outcomes or strata were (a priori) more important, weights could be
adjusted accordingly.
An interesting example where weighted average summary measures like ψ∗ are useful
is as follows. In Kangovi et al. (2017), a follow-up study to Kangovi et al. (2014), patients
were asked (prior to randomization) which of K outcomes they would like to focus on for
improvement, so that V ∈ {1, ..., K} indicates this choice. Investigators were interested in
the overall average effect of treatment A on patients’ selected outcomes, which is a special
case of the weighted summary in (15). Specifically, by selecting wk(V ) = 1(V = k) the
above summary measure reduces to
K∑
k=1
P(V = k)
{
E(Y 1k − Y 0k | V = k)
sd(Y 0k | V = k)
}
.
This is a weighted average of the scaled effects γk(k) on selected outcomes (among patients
selecting these outcomes), where the weights equal the proportion of patients choosing
to focus on each outcome. It should be noted, of course, that these summary measures
can provide an obscured view of the multivariate effects γk(v), k = 1, ..., K, when they
are heterogeneous; thus in practice such summary measures should be presented alongside
estimates of outcome-specific effects.
The efficient influence function for the parameter ψ∗ in (15) is given by
K∑
k=1
wk(V)
{
ϕ
(v)
k (Z) + γk(V)
}
− ψ∗ (16)
where ϕ
(v)
k (Z) is the efficient influence function for the v-specific effect γk(v) given by
1(V = v)
P(V = v)
(
φ1k(Z)− φ0k(Z)
sd(Y 0k | V)
− γk(v)
[
φ2k(Z) + E{(Y 0k )2 | V} − 2E(Y 0k | V)φ0k(Z)
2 sd(Y 0k | V)2
])
.
Therefore, as in previous sections, Wald-type confidence intervals for ψ∗ can be constructed
by estimating the values of the influence function in (16) and using the corresponding
empirical standard error.
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4 Simulation Study
To illustrate some of our proposed methods and explore finite-sample performance, we
simulated data with K = 4 outcomes from the following model:
X ∼ N(0, I4),
A | X ∼ Bernoulli{pi(x)},
pi(x) = expit{(2x1 − 4x2 + 2x3 − x4)/4},
Yk | X, A ∼ N{µk(x, a), k2},
µk(x, a) = k
∑
j 6=k
(−1)j+k−1xj + 2(k − λ)a.
For the main setting we consider (where λ = 2), the above model gives true values of
E(Y 1k − Y 0k ) = 2(k − 2) and sd(Y 0k ) = 2k, so that ψk = 1− 2/k, i.e.,
ψ = (−1, 0, 1/3, 1/2)T.
The above model also implies that that ηk(x, a) follows a linear model that is quadratic in
the covariates and includes all two-way interactions.
To analyze the above simulated data, we considered estimation of the scaled effect pa-
rameter ψ, as well as testing of the homogeneous effects hypothesis discussed in Section
3.3. Here we implemented the proposed estimating equation version of our estimator ψˆ,
but also give results for the TMLE version in Section 7 of the Supplementary Materials
(with R code for both given in Section 6). This estimator depends on estimates of the nui-
sance functions (pi, µ, η), which we constructed using correctly specified parametric models.
We used parametric models to ease computation and focus ideas, but in practice we sug-
gest using more flexible methods to minimize risk of model misspecification. To assess
potential impacts of such model misspecification in our simulation setup, we fit paramet-
ric models with transformed versions of the covariates, using the same transformations as
Kang & Schafer (2007). Confidence intervals were constructed using the closed-form in-
fluence function-based approach, which is technically only valid under correct modeling of
pi; in practice the bootstrap could be used if misspecification of pi is possible. Results for
estimating ψ are given in Table 1 (with RMSE scaled by
√
n for easier interpretation).
The simulations results reflect what is expected based on theory. In particular, the
scaled effect ψ was estimated with small bias whenever either pi or (µ, η) were correctly
modeled, indicating the double robustness of our approach. Of course, if all nuisance
estimators are misspecified, no method can promise small bias. Finite-sample biases under
correct specification of either pi or (µ, η) were quite small even when n = 200, and for
n = 1000 they were almost always zero after rounding (i.e., less than 0.0005). When all
nuisance estimators were correctly modeled, coverage was very close to the nominal 95%
level, especially for the n = 1000 case. Under misspecification of either pi or (µ, η), coverage
was usually close to 95% even without any theoretical guarantees, while (as expected)
coverage was poor under complete misspecification. In cases where one of pi or (µ, η) was
incorrectly modeled, we expect the bootstrap to provide improved performance. Results
for the TMLE estimator were similar (see Section 7 of the Supplementary Materials).
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Table 1: Results for estimating ψ across 1000 simulations.
Correct Model n = 200 n = 1000
& Parameter Bias SE RMSE Cov Bias SE RMSE Cov
Both ψ1 -0.02 0.14 2.03 90.2% -0.00 0.06 1.97 93.5%
ψ2 0.00 0.09 1.32 93.0% 0.00 0.04 1.25 95.6%
ψ3 -0.00 0.09 1.27 94.9% -0.00 0.04 1.21 94.3%
ψ4 0.02 0.11 1.54 92.8% 0.00 0.05 1.52 93.9%
Trt ψ1 -0.05 0.16 2.67 93.7% -0.01 0.08 2.63 96.8%
ψ2 0.02 0.14 1.96 97.5% 0.00 0.06 1.88 98.3%
ψ3 -0.01 0.09 1.29 93.8% -0.00 0.04 1.32 95.6%
ψ4 0.03 0.16 2.54 95.9% 0.01 0.07 2.35 97.2%
Out ψ1 -0.02 0.14 1.97 88.1% -0.00 0.06 1.74 93.0%
ψ2 0.01 0.09 1.34 93.6% 0.00 0.04 1.23 95.3%
ψ3 0.00 0.09 1.29 93.3% -0.00 0.04 1.16 95.0%
ψ4 0.01 0.11 1.60 89.2% 0.01 0.05 1.48 91.8%
None ψ1 -0.31 0.20 5.24 56.5% -0.30 0.09 9.90 5.8%
ψ2 0.22 0.15 3.79 59.2% 0.23 0.07 7.56 6.6%
ψ3 -0.04 0.09 1.43 92.2% -0.03 0.07 2.59 87.6%
ψ4 0.36 0.21 5.93 35.9% 0.37 0.09 11.98 1.7%
For the hypothesis testing portion of the simulation study, we used the proposed test
statistic Tn based on the estimators ψˆ described earlier, with the covariance estimator
Σˆ proposed in Section 3.3 (the estimated covariance of the estimated influence function
values). We implemented the approach under the null setting λ = 0 to assess type I
error (when λ = 2 and the homogeneous effect hypothesis fails to hold, our approach gave
100% power in all settings). As before, our theory only guarantees correct error control
under correct model specification for both µ and (pi, η) when using the closed-form variance
estimator.
Table 2: Results for testing homogeneity across 1000 simulations.
Correct Type I Error
Model n = 200 n = 500 n = 1000 n = 5000
Both 11.4% 8.4% 5.8% 5.5%
Trt 9.0% 6.4% 5.6% 3.8%
Out 13.5% 9.3% 7.7% 7.5%
None 55.7% 91.2% 99.2% 100%
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The simulations show that our test approximately controls type I error at nominal rates
in large samples, if either working model is correct. There is some anticonservative bias
for smaller sample sizes, as is often the case for generalized Wald tests (Boos & Stefanski
2013). We expect this could be ameliorated by using the bootstrap instead of a closed-form
variance estimator. Although the closed-form variance estimator does not guarantee error
control under misspecification, the type I error was relatively close to 5% as long as one
of pi or (µ, η) was correctly modeled. Again TMLE results are given in Section 7 of the
Supplementary Materials; in this setting the TMLE version of our estimator gave inflated
type I error relative to the estimating equation results presented in the main text.
5 Application
Here we apply our proposed methods to a recent trial (Kangovi et al. 2017) studying the
effects of a (randomized) community health worker intervention on four chronic disease-
related outcomes: cigarettes per day (CPD), systolic blood pressure (SBP), HbA1c, and
body mass index (BMI). At baseline each subject was asked which of the outcomes he
or she would prefer to focus on, and the primary goal of the study was to learn whether
the intervention affected patients’ focus outcomes. Each outcome was measured in terms
of change between study enrollment and 6-month follow-up, so negative values indicate
improvement. Kangovi et al. (2017) give full details of the study population and design.
In our analysis we adjust for baseline outcomes, age, gender, and the selected focus out-
come, and we used the cross validation-based Super Learner (van der Laan & Rose 2011) to
combine parametric models (linear for the outcome, logistic for the treatment), generalized
additive models, and random forests. Note however that here covariate adjustment is only
for the purposes of increasing efficiency, since the intervention was completely randomized
(i.e., our propensity score model is guaranteed to be correctly specified). We estimate the
scaled effects from Section 3.1, test effect homogeneity as in Section 3.3, estimate how
effects vary with V = selected outcomes as in Section 3.4, and finally estimate the average
effect on selected outcomes via the summary measure approach from Section 3.5.
Results are displayed in Figure 1. The scaled effect estimates (with non-simultaneous
95% confidence intervals) were -0.22 (-0.36, -0.08) for CPD, 0.09 (-0.04, 0.22) for SBP,
-0.08 (-0.22, 0.05) for HbA1c, and 0.02 (-0.15, 0.19) for BMI. These results indicate that
the intervention was effective in reducing cigarettes smoked per day, yielding a decrease
of roughly a fifth of a standard deviation (of pre-post differences). The null hypothesis
of zero scaled effect for CPD was in fact rejected at level 0.05 after Bonferroni correction
for multiple testing (since p = 0.001 < 0.05/4). There was some effect homogeneity, as
indicated in the left panel of Figure 1 and by the fact that the homogeneous effects test from
Section 3.3 was rejected (p = 0.031). Hence we have evidence that the intervention affects
different outcomes differently. Finally we also see that effects were generally stronger for
outcomes that patients selected to focus on. However it is still only the CPD outcome for
which we can reject a non-zero effect at the 0.05 level (p = 0.003). The estimated average
effect on selected outcomes was a tenth of a standard deviation, and significantly different
from zero. However it is clear that much of this effect comes from the effects on smoking.
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Figure 1: Estimates of scaled effects ψk (left) and effects on focus outcomes γk(k) (right),
with pointwise 95% CIs. Also shown is the p-value for testing effect homogeneity (left) and
the estimated summary effect on selected outcomes with 95% CI (right).
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6 Discussion
In this paper we proposed flexible methods for estimating and testing effects in studies with
multiple outcomes. We developed nonparametric doubly robust methods for estimating
effects scaled using mean-variance and interquartile-range standardizations, including effect
modification and weighted summary measures, and constructed a test of effect homogeneity.
We expect our work to be important for both randomized trials and observational studies,
and feel our distribution-free results fill an important gap in the literature.
There are a number of important future directions to this research. In an upcoming
paper we will apply the methods to explore effects of a community health worker interven-
tion in a patient-centered study that allows patients to choose to focus on certain outcomes
rather than others, as briefly described in Section 3.5. It will also be useful to develop tests
of other hypotheses beyond homogeneity (e.g., tests of no effect), to more thoroughly ex-
plore the implementation and performance of the bootstrap or other methods for weakening
assumptions for valid inference, and to consider an asymptotic regime in which K = Kn
increases with sample size (which may more accurately represent studies with many out-
comes).
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Supplementary Materials for
“Estimating scaled treatment effects
with multiple outcomes”
1 Proof of double robustness of ψˆk
Using iterated expectation, it is straightforward to show that φak and φ2k are doubly robust
in the sense that
E{φak(Z; pi, µ)} = E(Y ak )
E{φ2k(Z; pi, η)} = E{(Y 0k )2}
as long as either pi = pi or (µ, η) = (µ, η), not necessarily both.
Thus under standard Glivenko-Cantelli regularity conditions on the estimators (pˆi, µˆ, ηˆ)
and their limits (pi, µ, η), as long as either pi = pi or (µ, η) = (µ, η), then we have
Pn
{
φak(Z; pˆi, µˆ)
}
p→ E(Y ak )
Pn
{
φ2k(Z; pˆi, ηˆ)
}
p→ E{(Y 0k )2}.
Therefore, by the continuous mapping theorem (and if sd(Y 0k ) > 0 so ψk is well-defined),
we have
ψˆk
p→ E(Y
1
k )− E(Y 0k )√
E{(Y 0k )2} − E(Y 0k )2
= ψk
as long as either pˆi or (µˆ, ηˆ) converge to the truth, and so ψˆk is doubly robust.
Double robustness can also be seen via the efficient influence function, since
E
(
φ1k − φ0k
sd(Y 0k )
− ψk
[
φ2k + E{(Y 0k )2} − 2E(Y 0k )φ0k
2sd(Y 0k )
2
])
= 0
=⇒ ψk = 2sd(Y
0
k )E(φ1k − φ0k)
E[φ2k + E{(Y 0k )2} − 2E(Y 0k )φ0k]
=
E(Y 1k − Y 0k )
sd(Y 0k )
and the last step follows as long as either pi = pi or (µ, η) = (µ, η).
1
2 Proof of asymptotic normality
Let βk = (β0k, β1k, β2k)
T with
β0k = E(Y 0k ) , β1k = E(Y 1k ) , β2k = E{(Y 0k )2}
and define the corresponding estimator βˆk = (βˆ0k, βˆ1k, βˆ2k)
T for
βˆ0k = Pn{φ0k(Z; pˆi, µˆ)} , βˆ1k = Pn{φ1k(Z; pˆi, µˆ)} , βˆ2k = Pn{φ2k(Z; pˆi, ηˆ)}.
Let φk = (φ0k, φ1k, φ2k)
T, and suppose that
1. (pi, µ, η) = (pi, µ, η),
2. ||pˆi − pi|| = oP(n−1/4) and (||µˆ− µ||+ ||ηˆ − η||) = oP(n−1/4),
3. (pi, µ, η) and (pˆi, µˆ, ηˆ) fall in Donsker classes.
Then by for example Theorem 5.31 for Z-estimators from van der Vaart (2000) we have
βˆk − βk = Pn
{
φk(Z; pi, µ, η)− βk
}
+ oP(1/
√
n).
Now since ψˆk = g(βˆk) = (βˆ1k− βˆ0k)/
√
βˆ2k − βˆ20k, an application of the delta method (with
detailed calculations given in the next section of these Supplementary Materials) yields
ψˆk − ψk = Pn
[
(∇g)
{
φk(Z; pi, µ, η)− βk
}]
+ oP(1/
√
n)
= Pn
[
φ1k − φ0k√
β2k − β20k
− ψk
{
φ2k + β2k − 2β0kφ0k
2(β2k − β20k)
}]
+ oP(1/
√
n).
Asymptotic normality then follows immediately from the central limit theorem.
3 Derivation of efficient influence function
That the efficient influence function is
ϕk =
φ1k − φ0k
sd(Y 0k )
− ψk
[
φ2k + E{(Y 0k )2} − 2E(Y 0k )φ0k
2sd(Y 0k )
2
]
follows from the fact that (φak − βak) and (φ2k − β2k) are the efficient influence functions
for βak and β2k, respectively, together with the delta method.
Specifically, for ψk = g(βk) = (β1k − β0k)/
√
β2k − β20k we have
∇g =
{
∂g(βk)
∂β0k
,
∂g(βk)
∂β1k
,
∂g(βk)
∂β2k
}
=
1√
β2k − β20k
{(
β0kβ1k − β2k
β2k − β20k
)
, 1,
1
2
(
β0k − β1k
β2k − β20k
)}
=
1
sd(Y 0k )
{
ψkβ0k/sd(Y
0
k )− 1, 1,−ψk/2sd(Y 0k )2
}
2
so that, letting τk = sd(Y
0
k ),
(∇g)
(
φk − βk
)
=
1
τk
[(
β0k
τk
ψk − 1
)
(φ0k − β0k) + (φ1k − β1k)− ψk(φ2k − β2k)/2τk
]
=
(φ1k − β1k)− (φ0k − β0k)
τk
− ψk
2τ 2k
{
(φ2k − β2k)− 2(φ0k − β0k)β0k
}
=
(
φ1k − φ0k
τk
)
− ψk − ψk
(
φ2k − 2φ0kβ0k + β2k
2τ 2k
)
+ ψk
=
φ1k − φ0k
sd(Y 0k )
− ψk
[
φ2k + E{(Y 0k )2} − 2E(Y 0k )φ0k
2sd(Y 0k )
2
]
as given in the main text.
4 Efficient influence function (quantile case)
As discussed by Dı´az (2015) the efficient influence function for ξaq = F
−1
ak (q) is given by
φqak =
−1
P(Yk = ξaq)
[
1(A = a)
pi(a | X)
{
1(Yk ≤ ξaq)− νk(ξaq | X, a)
}
+ νk(ξaq | X, a)− q
]
.
Letting ξk = (ξ1,.5, ξ0,.5, ξ0,.75, ξ0,.25), then if ξˆk is an efficient estimator (e.g., solving the
efficient influence function estimating equation up to order oP(1/
√
n)) we have
ξˆk − ξk = Pn(φqk) + oP(1/
√
n)
where φqk = (φ
.5
1k, φ
.5
0k, φ
.75
0k , φ
.25
0k )
T. Then by the delta method the efficient influence function
for ψqk = (ξ1,.5 − ξ0,.5)/(ξ0,.75 − ξ0,.25) is given by
(φ.51k − φ.50k)− ψqk(φ.750k − φ.250k )
ξ0,.75 − ξ0,.25 .
5 Asymptotic distribution of test statistic
This section relies on the asymptotic linearity result from Section 2. Under the null hy-
pothesis, due to the banded structure of C we have Cψ = 0, so that since
ψˆ −ψ = Pn(ϕ) + oP(1/
√
n)
it follows that
Cψˆ = Pn(Cϕ) + oP(1/
√
n).
Therefore
√
nCψˆ  N{0, cov(Cϕ)} by the central limit theorem, and similarly for the
corresponding quadratic form we have
(
√
nCψˆ)Tcov(Cϕ)−1(
√
nCψˆ) = n(Cψˆ)T(CΣCT)−1(Cψˆ) χ2K−1.
By Slutsky’s theorem the same result holds when Σˆ
p→ Σ replaces Σ.
3
6 R code for simulation
library(tmle)
expit <- function(x){ exp(x)/(1+exp(x)) }
logit <- function(x){ log(x/(1-x)) }
n <- 1000
nsim <- 500
cor <- "both" # options for correct model(s): both, trt, out, none
nullcase <- F
## note: to implement tmle version replace ‘Qinit$Q’ with ‘Qstar’
## create matrix to store results
res.names <- c(paste("psi",1:4,sep=""),paste("psi.se",1:4,sep=""),"tn","pval")
res <- data.frame(matrix(NA,nrow=nsim,ncol=length(res.names)))
colnames(res) <- res.names; i <- 1
for (i in 1:nsim){
print(i); flush.console()
## simulate data
x <- matrix( rnorm(4*n) , nrow=n); colnames(x) <- paste("x",1:4,sep="")
pi <- expit((2*x[,1] -4*x[,2] + 2*x[,3] - x[,4])/4)
a <- rbinom(n,1,pi)
kmat <- matrix(rep(1:4,n),nrow=n,byrow=T)
mu <- kmat * cbind( x[,2]-x[,3]+x[,4], x[,1]+x[,3]-x[,4],
-x[,1]+x[,2]+x[,4], x[,1]-x[,2]+x[,3] ) + 2*(kmat-2*(!nullcase))*a
y <- mu + matrix(rnorm(4*n,sd=kmat),nrow=n); colnames(y) <- paste("y",1:4,sep="")
## construct covariates
xm <- cbind(exp(x[,1]/2), 10 + x[,2]/(1+exp(x[,1])),
(.6+x[,1]*x[,3]/25)^3, (x[,2]+x[,4]+20)^2)
if (cor=="both"){ x <- data.frame(cbind(x,x)) }
if (cor=="out"){ x <- data.frame(cbind(xm,x)) }
if (cor=="trt"){ x <- data.frame(cbind(x,xm)) }
if (cor=="none"){ x <- data.frame(cbind(xm,xm)) }
x <- cbind(x, x[,5:8]^2, x[,5]*x[,6], x[,5]*x[,7], x[,5]*x[,8],
x[,6]*x[,7], x[,6]*x[,8], x[,7]*x[,8])
colnames(x) <- c(paste("gx",1:4,sep=""), paste("qx",1:4,sep=""),
paste("q2x",1:10,sep=""))
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## estimation/inference for psi
infvals <- NULL; for (j in 1:4){
## estimate b1=EY1, obtain inf fn vals
b1.tmle <- tmle(Y=y[,j],A=NULL,W=x,Delta=a,
g.Deltaform=Delta~gx1+gx2+gx3+gx4, Qform=Y~qx1+qx2+qx3+qx4)
phi1 <- a*(y[,j]-b1.tmle$Qinit$Q[,2]) / b1.tmle$g.Delta$g1W[,1] +
b1.tmle$Qinit$Q[,2]; b1 <- mean(phi1)
## estimate b0=EY0, obtain inf fn vals
b0.tmle <- tmle(Y=y[,j],A=NULL,W=x,Delta=1-a,
g.Deltaform=Delta~gx1+gx2+gx3+gx4, Qform=Y~qx1+qx2+qx3+qx4)
phi0 <- (1-a)*(y[,j]-b0.tmle$Qinit$Q[,2]) / b0.tmle$g.Delta$g1W[,1] +
b0.tmle$Qinit$Q[,2]; b0 <- mean(phi0)
## estimate b2=E{(Y0)^2}, obtain inf fn vals
b2.tmle <- tmle(Y=y[,j]^2,A=NULL,W=x,Delta=1-a, g.Deltaform=Delta~gx1+gx2+gx3+gx4,
Qform=Y~q2x1+q2x2+q2x3+q2x4+q2x5+q2x6+q2x7+q2x8+q2x9+q2x10)
phi2 <- (1-a)*(y[,j]^2-b2.tmle$Qinit$Q[,2]) / b2.tmle$g.Delta$g1W[,1] +
b2.tmle$Qinit$Q[,2]; b2 <- mean(phi2)
## estimate scaled effect psi
res[i,j] <- (b1-b0)/sqrt(b2-b0^2)
## get inf fn vals for psi
infvals <- cbind(infvals, (phi1 - phi0)/sqrt(b2-b0^2) - res[i,j] *
(phi2 + b2 - 2*b0*phi0)/(2*(b2-b0^2)) ) }
## compute variance based on inf fn vals
res[i,5:8] <- sqrt(diag(cov(infvals))/n)
## test homogeneity hypothesis
cmat <- rbind(c(1,-1,0,0),c(0,1,-1,0),c(0,0,1,-1))
psi <- t(res[i,1:4]); sigma <- cov(infvals)
res$tn[i] <- n * t(cmat %*% psi) %*% solve( cmat %*% sigma %*% t(cmat)) %*%
(cmat %*% psi); res$pval[i] <- pchisq(res$tn[i],df=3,lower.tail=F)
}
## summarize simulation results
if (nullcase==F){ psi0 <- c(-1,0,1/3,.5) }; if (nullcase==T){ psi0 <- rep(1,4) }
psimat <- matrix(psi0,nrow=nsim,ncol=4,byrow=T)
(resmat <- data.frame(
bias=apply(res[,1:4],2,mean,na.rm=T)-psi0, se=apply(res[,1:4],2,sd,na.rm=T),
med.se=apply(res[,5:8],2,median,na.rm=T),
rmse=sqrt(n*apply((res[,1:4]-psimat)^2,2,mean,na.rm=T)),
cov=apply((res[,1:4]-1.96*res[,5:8]<psimat) &
(res[,1:4]+1.96*res[,5:8]>psimat),2,mean, na.rm=T )) )
mean(res$pval<=0.05, na.rm=T)
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7 TMLE simulation results
Table 3: Results for estimating ψ via TMLE across 500 simulations.
Correct Model n = 200 n = 1000
& Parameter Bias SE RMSE Cov Bias SE RMSE Cov
Both ψ1 -0.02 0.14 1.98 87.8% -0.00 0.06 1.97 94.0%
ψ2 0.01 0.09 1.31 92.2% 0.00 0.04 1.27 95.0%
ψ3 -0.01 0.09 1.22 93.8% -0.00 0.04 1.26 93.8%
ψ4 0.02 0.11 1.51 92.4% 0.00 0.05 1.55 94.6%
Trt ψ1 -0.05 0.16 2.42 91.6% -0.01 0.07 2.29 96.8%
ψ2 0.02 0.11 1.61 97.6% 0.00 0.05 1.64 97.0%
ψ3 -0.01 0.09 1.26 93.8% -0.00 0.04 1.32 94.2%
ψ4 0.04 0.12 1.87 96.6% 0.01 0.05 1.71 97.8%
Out ψ1 -0.02 0.12 1.77 88.6% -0.00 0.05 1.69 92.6%
ψ2 0.01 0.09 1.26 91.8% 0.00 0.04 1.24 93.2%
ψ3 -0.00 0.09 1.24 93.4% -0.00 0.04 1.21 93.6%
ψ4 0.01 0.09 1.33 92.4% 0.00 0.04 1.34 94.4%
None ψ1 -0.34 0.20 5.50 49.8% -0.31 0.09 10.25 5.0%
ψ2 0.24 0.15 4.00 51.6% 0.23 0.07 7.67 5.4%
ψ3 -0.03 0.09 1.35 91.6% -0.03 0.04 1.52 90.8%
ψ4 0.39 0.18 6.11 30.8% 0.38 0.08 12.38 0.8%
Table 4: Results for testing homogeneity via TMLE across 1000 simulations.
Correct Type I Error
Model n = 200 n = 500 n = 1000 n = 5000
Both 12.9% 9.1% 6.6% 6.1%
Trt 10.3% 7.2% 6.5% 3.2%
Out 13.6% 10.2% 7.9% 7.6%
None 58.2% 92.9% 99.5% 100.0%
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